Ticagrelor Dosing for Ischemic Risk and Bleeding Trade-off
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiplatelet therapies for patients with a history of myocardial infarction or acute coronary syndrome often balance ischemic risk reduction with an increased risk of bleeding, and the optimal intensity of platelet inhibition for long-term secondary prevention is not established, with existing P2Y12 receptor antagonists like clopidogrel having variable efficacy and bleeding risks.
Innovation Solution
Administering ticagrelor, a direct-acting reversible P2Y12 receptor antagonist, in combination with aspirin, at a dose of 60 mg or 90 mg twice daily to reduce the rate of cardiovascular death, myocardial infarction, or stroke, while potentially lowering the risk of bleeding by adjusting the intensity of platelet inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiplatelet therapies are used to reduce ischemic risk, then the rate of cardiovascular death, myocardial infarction, or stroke is reduced, but the risk of bleeding increases
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage intensity of ticagrelor (60 mg or 90 mg twice daily) to optimize the balance between platelet inhibition efficacy and bleeding risk. This dose adjustment strategy allows customization of the therapeutic effect to match individual patient needs, thereby reducing ischemic events while minimizing harmful bleeding complications.
Solution Approach 2:
The patent employs partial action by using ticagrelor at optimized doses that provide sufficient platelet inhibition to prevent ischemic events without excessive inhibition that would lead to increased bleeding risk. The dosing regimen is calibrated to achieve the minimum effective antiplatelet effect needed for secondary prevention, avoiding over-inhibition of platelet function.
2Reliability
If existing P2Y12 receptor antagonists like clopidogrel are used, then platelet inhibition is achieved, but the efficacy and bleeding risks show high variability
Solution Approach 1:
The patent addresses variability by implementing optimized dosing parameters for ticagrelor (60 mg or 90 mg twice daily) that produce more consistent and predictable platelet inhibition compared to other P2Y12 antagonists. The direct-acting mechanism of ticagrelor, combined with optimized dosing, reduces inter-patient variability in response and provides more reliable therapeutic outcomes.
Solution Approach 2:
The patent substitutes the prodrug mechanism of clopidogrel with the direct-acting mechanism of ticagrelor. Ticagrelor does not require hepatic activation and directly binds to the P2Y12 receptor, eliminating the variability associated with metabolic activation and providing more predictable and reliable platelet inhibition across different patient populations.
3Reliability
If higher intensity platelet inhibition is used to maximize ischemic protection, then the composite endpoint of cardiovascular death, myocardial infarction, or stroke is reduced, but the risk of fatal bleeding increases
Solution Approach 1:
The patent applies partial action by using optimized doses of ticagrelor that provide adequate but not excessive platelet inhibition. The dosing regimen is calibrated to achieve sufficient protection against ischemic events while avoiding the excessive antiplatelet effect that would lead to increased fatal bleeding risk. This optimized intensity strikes the right balance between benefit and harm.
Solution Approach 2:
The patent employs dynamic dosing strategies where the intensity of platelet inhibition can be adjusted based on individual patient risk profiles. The twice-daily dosing allows for dynamic control of antiplatelet effect, enabling optimization of protection against ischemic events while minimizing bleeding risk through flexible dose selection (60 mg or 90 mg).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of ticagrelor with aspirin significantly reduces the composite endpoint of cardiovascular death, myocardial infarction, or stroke, with a trend towards reduced fatal bleeding, as demonstrated by the PEGASUS-TIMI 54 study, improving the risk-benefit profile for long-term secondary prevention in patients with a history of myocardial infarction.
Implementation Method 1
Ticagrelor is a direct-acting reversible binding P2Y12 receptor antagonist that inhibits platelet activation and aggregation mediated by the P2Y12 ADP-receptor
Implementation Method 2
ticagrelor is also known to increase local endogenous adenosine levels by inhibiting equilibrative nucleoside transporter-1 (ENT-1)
Implementation Method 3
Adenosine has been documented to have a number of effects that include: vasodilation, cardioprotection, platelet inhibition
Data Source
AI summary
The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.